Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study on the Safety and Efficacy of in Vivo CAR-T Cell Therapy (TI-0032-III Injection) for the Treatment of Relapsed and Refractory Autoimmune Diseases

NCT07413341 is registered in ClinicalTrials.gov with Therorna as lead sponsor.

NCT NCT07413341
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07413341 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study on the Safety and Efficacy of in Vivo CAR-T Cell Therapy (TI-0032-III Injection) for the Treatment of Relapsed and Refractory Autoimmune Diseases
Lead sponsor
Therorna
Phase
Phase 1
Overall status
Recruiting
Start date
January 22, 2026
Completion date
January 30, 2027
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anca associated systemic vasculitis, inflammatory myopathy, sjogren's syndrome (ss), systemic lupus erythematosus (sle), systemic sclerosis (ssc)